InspireMD, Inc. Q2 2026 Earnings Call Summary
InspireMD reported Q2 2026 results, citing flat revenue from a voluntary recall of its CGuard Prime 135 delivery system. Management said $734,000 in customer credits offset underlying U.S. growth, with a $612,000 inventory impairment and negative reported gross margin of 43.7%. It cut staff 20% and expects about $9M annual savings. FDA decisions for CGuard Prime 80 (TCAR) and CGuard CAS are targeted for Q4 2026, with Prime 135 reentry in H1 2027.
How this was made
The 30-second read
Why it matters
Traders can update probability-weighted timelines for (1) FDA approval of CGuard Prime 80 (TCAR) and CGuard CAS in Q4 2026, (2) potential accelerated review for the redesigned CGuard Prime 135 delivery system, and (3) SwitchGuard’s back-half 2027 approval path, while also reassessing near-term cash runway after recall and restructuring charges.
Market read
The article provides concrete recall-related financial impacts and specific FDA timing targets that can move valuation via updated commercialization probabilities.
What to watch
Cash fell to $30.4M and restructuring charges are expected in Q3 2026, which could increase dilution or financing risk before relaunch revenue materializes.
Background
This is a Q2 2026 earnings call summary focused on InspireMD’s CGuard stent platform recall, cost actions, and FDA approval/relaunch timelines.
Market effects
Highlights how delivery-system recalls can shift FDA timelines and force cost restructuring in medical device stent/TCAR workflows.
No specific regional market impact beyond international growth commentary.
US FDA approval timing remains the key driver for global commercialization expectations.
Counterpoint
The optimism around accelerated review and pent-up demand may be overly optimistic given the stated long poles (biocompatibility testing and statutory review).
Key entities
- companyInspireMD, Inc.
Subject of the earnings call summary; discussed recall impacts, restructuring, cash position, and FDA relaunch milestones for CGuard and SwitchGuard.
- productCGuard Prime 135
Voluntarily recalled delivery system; drove customer credits, inventory impairment, and a redesign/reentry plan.
- productCGuard Prime 80 (TCAR) and CGuard CAS
Management anticipates potential FDA approval for both in Q4 2026.
- productSwitchGuard neuroprotection system
Tracking toward back-half 2027 US approval; CGUARDIANS III enrollment underway.
